A little more than 200 temporary medical staff ended up being sent to hospitals, while monoclonal antibody treatments averaged more than $5,600 per patient.
Celltrion submitted an IND application for a global Phase III clinical trial of inhaled antibody cocktail therapy with CT-P59 and CT-P63; the company expects to enrol 2,200 patients with mild-to-moderate
With Omicron looming and cases surging, researchers are racing to deliver new therapeutics. But nearly two years in, only a few have proven safe and effective.
South Korean pharmaceutical giant Celltrion has started a Phase I clinical trial of an inhalable form of Covid-19 treatment Regkirona in Australia, according to industry sources on October 22.